P385 EFFECTIVENESS OF DENOSUMAB IN REDUCING BACK PAIN AND IN IMPROVING BONE MINERAL DENSITY AND HEALTH RELATED QUALITY OF LIFE: 1-YEAR FOLLOW-UP PROSPECTIVE STUDY I N POSTMENOPAUSAL WOMEN WITH VERTEBRAL FRAGILITY FRACTURES

Objective: To assess the effectiveness of denosumab in reducing back pain related disability and in improving bone mineral density (BMD) and Health Related Quality of Life (HRQoL) in osteoporotic postmenopausal women with vertebral fractures. Material and Methods:We enrolled women aged ≥50 years with a diagnosis of postmenopausal osteoporosis that had experienced at least one vertebral fragility fracture. We administered subcutaneous denosumab (60 mg/every 6 months) and a supplementation of calcium carbonate (500- 1000 mg/day) and cholecalciferol (800 IU/day) for 1 year. We assessed at the baseline (T0), after 6 months (T1), and after 12 months (T2) of treatment the following outcomes: back pain related disability, assessed by Spine Pain Index (SPI), and HRQoL, using the 12-Item Short Form Health Survey (SF-12), with Physical (PCS) and Mental Health Composite Scores (MCS) and the European Quality of Life - 5 Dimensions - 3 Levels (EuroQol-5D-3L) index (EQ-5D-3L index) and the EuroQol-Visual Analogue Scale scores (EQ VAS). Moreover, we evaluated lumbar spine (LS) and femoral neck (FN) BMD at T0 and T2. Results: We assessed 140 women, mean aged 74.9±8.8 years, with a mean BMI of 26.1±3.9 kg/m2. Results are reported in Table 1. Conclusions: Our data analysis demonstrated that 1-year treatment with denosumab was significantly effective in reducing back pain related disability and in improving BMD and HRQoL in a cohort of postmenopausal women with at least one vertebral fracture.